RecruitingNCT04132895
ICONIC: Improving Outcomes Through Collaboration in OsteosarComa
Studying Osteosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University College, London
- Principal Investigator
- Sandra Strauss, MDUniversity College Hospitals London
- Intervention
- observational only, no interventions are prescribed in protocol.(other)
- Enrollment
- 300 enrolled
- Eligibility
- All sexes
- Timeline
- 2019 – 2027
Study locations (22)
- University College Hospitals London NHS Foundation Trust, London, Greater London, United Kingdom
- NHS Grampian Health Board, Aberdeen, United Kingdom
- Birmingham Women's and Childrens NHS Foundation Trust, Birmingham, United Kingdom
- The Royal Orthopaedic Hospital NHS Foundation Trust, Birmingham, United Kingdom
- University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
- Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
- Cardiff and Vale University LHB, Cardiff, United Kingdom
- NHS Lothian Health Board, Edinburgh, United Kingdom
- NHS Greater Glasgow and Clyde Health Board, Glasgow, United Kingdom
- Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
- University Hospitals of Leicester NHS Trust, Leicester, United Kingdom
- Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom
- The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, United Kingdom
- Manchester University NHS Foundation Trust, Manchester, United Kingdom
- The Christie NHS Foundation Trust, Manchester, United Kingdom
- +7 more locations on ClinicalTrials.gov
Collaborators
Bone Cancer Research Trust
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04132895 on ClinicalTrials.govOther trials for Osteosarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07477457A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With OsteosarcomaMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1NCT06492954Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed OsteosarcomaEmory University
- RECRUITINGNANCT07129226Musculoskeletal Cancers Remote Monitoring and CareCase Comprehensive Cancer Center
- RECRUITINGPHASE1NCT07144254Tegavivint With Gemcitabine in Patients With Relapsed or Refractory OsteosarcomaEmory University
- RECRUITINGPHASE1NCT07227571Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of Advanced Refractory or Recurrent/Progressive Osteosarcoma, FIERCe TrialFred Hutchinson Cancer Center
- RECRUITINGPHASE1NCT07052383Safety and Efficacy of DIT309 in Advanced Bone and Soft Tissue SarcomasTcelltech Inc.
- RECRUITINGPHASE1, PHASE2NCT06892678DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or OsteosarcomaMontefiore Medical Center
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05660408RNA Lipid Particles Targeting Pediatric Recurrent Intracranial Malignancies and Other systEmic Solid TumorsUniversity of Florida